According to TASS news agency, Russia's experimental cancer vaccine has successfully passed preclinical testing, demonstrating both safety and high effectiveness. The head of the Federal Medical and Biological Agency (FMBA), Veronika Skvortsova, shared the news at the Eastern Economic Forum (EEF), noting that the vaccine has been in development for several years, with the last three focusing on mandatory preclinical studies.

"The vaccine is now ready for use; we are awaiting official approval," Skvortsova stated, as reported by the Russian news agency. The preclinical results confirmed the drug's safety, even after repeated doses, and showed significant efficacy. Observations revealed tumor shrinkage and slower progression in 60-80% of cases, depending on the disease, along with improved survival rates.

Initially, the vaccine will target colorectal cancer, while work continues on vaccines for glioblastoma and specific forms of melanoma, including ocular melanoma, which are in the late stages of development, Skvortsova added.